BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Illinois Municipal Retirement Fund 4,370$1,515,0000.04%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 64,609$22,396,0000.04%
METROPOLITAN LIFE INSURANCE CO/NY 2,281$790,6860.04%
Maryland State Retirement & Pension System 3,024$1,048,0000.03%
GLOBEFLEX CAPITAL L P 405$140,0000.03%
Baird Financial Group, Inc. 34,845$12,079,0000.03%
Mitsubishi UFJ Asset Management Co., Ltd. 22,452$7,783,0000.03%
MetLife Investment Management, LLC 12,155$4,213,4090.03%
NORGES BANK 377,833$130,972,0310.03%
Chevy Chase Trust Holdings, LLC 23,694$8,214,0000.03%
Metis Global Partners, LLC 616$214,0000.03%
Hillsdale Investment Management Inc. 1,225$425,0000.03%
Diversified Trust Co 2,295$796,0000.03%
Magnetar Financial LLC 9,144$3,170,0000.03%
Jump Financial, LLC 2,196$761,0000.03%
Rathbones Group PLC 8,280$2,870,0000.03%
Ascent Group, LLC 716$276,0000.03%
STATE STREET CORP 1,568,279$543,628,0000.03%
Andra AP-fonden 3,200$1,109,0000.03%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 80,346$27,851,0000.03%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.